CDH22 hypermethylation is an independent prognostic biomarker in breast cancer. - Wikidata - wikimedia - TriplyDB

CDH22 hypermethylation is an independent prognostic biomarker in breast cancer.

CDH22 hypermethylation is an independent prognostic biomarker in breast cancer.

http://www.wikidata.org/entity/Q37609810

about

CDH22 hypermethylation is an independent prognostic biomarker in breast cancer.

http://www.wikidata.org/entity/Q37609810

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 24 January 2017

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

CDH22 hypermethylation is an independent prognostic biomarker in breast cancer.

@en

CDH22 hypermethylation is an independent prognostic biomarker in breast cancer.

@nl

type

label

CDH22 hypermethylation is an independent prognostic biomarker in breast cancer.

@en

CDH22 hypermethylation is an independent prognostic biomarker in breast cancer.

@nl

prefLabel

CDH22 hypermethylation is an independent prognostic biomarker in breast cancer.

@en

CDH22 hypermethylation is an independent prognostic biomarker in breast cancer.

@nl

P1433

Q37609810-DB655E83-BB27-4286-B4E3-7D30A341B9CB

P1476

Q37609810-60607396-564D-4904-ADDB-71C524CE31FF

P2093

Q37609810-1A38F82F-5641-402F-B849-CA8B561C5B4F

Q37609810-2F68B845-DB81-4F49-9BF7-55F13DE763EE

Q37609810-6D4C540E-2028-4B6E-8E72-6BCDFC20C558

Q37609810-74B4EB2E-6C3C-47F3-8376-EA641B6BDCC7

Q37609810-AC80CB2B-F3DD-487A-8402-E8AD59D6AC88

Q37609810-AFEB7B39-EA15-4378-B0FD-EE5FF6FB95A3

Q37609810-B4624860-60A3-4A92-99E1-43C488024C1A

Q37609810-EE560282-9A92-405D-B5C3-F3E0863AB7BC

Q37609810-F48A91A6-F593-45AB-B2EC-6CD771F2F837

P2860

Q37609810-1C74A3BC-2C11-4ED3-BCC1-CF343A91F15E

Q37609810-24209BF2-EA32-40C8-BE19-B65307708659

Q37609810-43D573B3-DD08-4677-B7D6-F3F28A3936C8

Q37609810-4B13EC6B-01E9-4222-B05C-45CDE1EE0137

Q37609810-4D713BF9-E84A-4A03-A357-8A8213F28059

Q37609810-4DC40E48-87B1-4D28-B9B8-82751EA20827

Q37609810-5C2ECF9C-1D2A-416C-9B97-4990BEB788EE

Q37609810-5F8A79B2-868A-43AC-9E44-A13011DB88DD

Q37609810-602873AA-09D2-4AC2-B257-1E0887B88306

Q37609810-7153934E-5C38-4013-83C9-6AF74F0E8642

P2888

Q37609810-7D15192E-E061-4575-A60A-83F599128C2E

P304

Q37609810-00DBC6C9-D8C5-4481-8FF8-12F5C0037228

P31

Q37609810-8B9CFBB4-4EAE-4E1B-9040-1B8896C471DB

P356

Q37609810-2D77E6FC-4041-4812-92F7-2CE3F8B83A13

P478

Q37609810-F7E7121A-077E-4504-8F36-E1227BB49398

P50

Q37609810-D6F789E2-CC8D-4A9D-AEBA-5EE7B03B14E8

P577

Q37609810-B0BA2BB7-9703-4115-9278-3DC05657EFB0

P6179

Q37609810-14A779E7-8362-4013-B64C-0E0D2376715B

P698

Q37609810-D20B2CB7-2FCF-46BD-91D6-CC9DDC58A635

P921

Q37609810-3F954B1B-4A86-4493-AF1F-9DE73883EEE3

P932

Q37609810-E2EA366E-91E3-4E67-9D01-5B9BD1D4D82C

P356

S13148-016-0309-Z

P1433

Clinical epigenetics

P1476

CDH22 hypermethylation is an independent prognostic biomarker in breast cancer

@en

P2093

Alicia Córdoba

http://www.w3.org/2001/XMLSchema#string

Ana Aramendia

http://www.w3.org/2001/XMLSchema#string

Ane Ulazia-Garmendia

http://www.w3.org/2001/XMLSchema#string

David Guerrero-Setas

http://www.w3.org/2001/XMLSchema#string

Francisco Vicente-García

http://www.w3.org/2001/XMLSchema#string

Idoia Blanco-Luquin

http://www.w3.org/2001/XMLSchema#string

Iñaki Monreal-Santesteban

http://www.w3.org/2001/XMLSchema#string

Saioa Mendaza

http://www.w3.org/2001/XMLSchema#string

Susana De La Cruz

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer screening in the United States, 2016: A review of current American Cancer Society guidelines and current issues in cancer screening

DNA methylation pathways and their crosstalk with histone methylation

Interaction of Shc with adaptor protein adaptins

Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up

Molecular cloning and characterization of a newly identified member of the cadherin family, PB-cadherin

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

DNA methylation epigenotypes in breast cancer molecular subtypes.

Cell-cell adhesion in the normal ovary and ovarian tumors of epithelial origin; an exception to the rule.

CDH22 expression is reduced in metastatic melanoma.

Aberrant GSTP1 promoter methylation is associated with increased risk and advanced stage of breast cancer: a meta-analysis of 19 case-control studies.

P2888

s13148-016-0309-z

P304

7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13148-016-0309-Z

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Esperanza Martin-Sanchez

P577

2017-01-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1074228263

http://www.w3.org/2001/XMLSchema#string

P698

28149335

http://www.w3.org/2001/XMLSchema#string

P921

P932

5270318

http://www.w3.org/2001/XMLSchema#string